Skip to main content
Therapeutic Advances in Hematology logoLink to Therapeutic Advances in Hematology
. 2017 Feb 13;8(4):153–156. doi: 10.1177/2040620717690316

Point-of-care ultrasonography (POCUS) in hemophilia A: a commentary on current status and its potential role for improving prophylaxis management in severe hemophilia A

Suchitra S Acharya 1,, Brittny Rule 2, Omar McMillan 3, Thomas J Humphries 4,*
PMCID: PMC5405898  PMID: 28491266

Abstract

In patients with severe hemophilia A, recurrent bleeding into joints results in increased morbidity and reduced quality of life. Prophylaxis using replacement factor products, especially when initiated early, has established benefits in terms of reducing joint bleeds and preserving joint function. Poor adherence to prophylactic regimens is a common cause for breakthrough bleeds and resultant arthropathy. Improving prophylaxis management, especially in the transitional age group, is a challenge. Here, we discuss the current status of ultrasonography (US) in hemophilia A, challenges in its wider implementation, and the potential for use of point-of-care US (POCUS) as an adjunct in the routine management of patients with hemophilia following prophylaxis regimens. Using POCUS, in which US is performed by trained hematologists and nonphysician operators (rather than comprehensive US performed by imaging specialists), specific clinical questions can be addressed in a time-efficient, user-friendly manner to promote adherence to prophylaxis and guide or modify treatment approaches. This review also discusses barriers to acceptance of POCUS as a part of routine management of patients with hemophilia, including questions related to its diagnostic accuracy, dependence on trained operators, agreement on appropriate scoring systems, and potential usefulness in patient management.

Keywords: adherence, arthropathy, hemophilia, magnetic resonance imaging, prophylaxis, ultrasonography


Severe hemophilia A is a bleeding disorder characterized by an inherited deficiency of plasma clotting factor VIII (levels <1%), which leads to persons with hemophilia (PWH) experiencing spontaneous bleeding events. At some point in their lifetime, most PWH experience joint bleeding or hemarthroses, primarily in the knees, ankles, and elbows. Over time, this repeated extravasation of blood into the joints leads to joint disease specifically referred to as hemophilic arthropathy [Acharya et al. 2011]. This is characterized by recurrent joint bleeding, inflammation, synovial hypertrophy, and cartilage destruction, leading to morbidity and reduced quality of life [Melchiorre et al. 2011].

Manco-Johnson and colleagues demonstrated that routine replacement with recombinant factor VIII, referred to as prophylaxis, reduces the incidence of joint hemorrhages and life-threatening hemorrhages and lowers the risk of joint damage among young boys with severe factor VIII deficiency [Manco-Johnson et al. 2007]. Therefore, early detection of joint bleeds in PWH is critical in the effort to preserve joint function. By detecting joint bleeds early in life using imaging technology, a patient may become more motivated and willing to initiate or continue prophylaxis. However, the maximum patient benefits of prophylaxis can be realized only if patients adhere to the prescribed regimen. Patients with hemophilia transitioning through their teen years (13 through 18 years of age) who are self-infusing, face challenges with prophylaxis and need emphasis on adherence and compliance to their prescribed prophylaxis at annual comprehensive visits to their hemophilia treatment center (HTC) [Young, 2012]. Visual evidence of good or poor compliance documented by ultrasonography (US) presented and discussed during HTC visits may serve to improve compliance. Published estimates of adherence to prophylaxis described by patients, caregivers, and prescribers vary widely from a very optimistic 80% to a low of 41% [Armstrong et al. 2015]. A recent study using a commercial database estimated that 66% of patients with severe hemophilia A or B were adherent <70% of the time [Armstrong et al. 2015].

Potential barriers to the use of point-of-care ultrasonography (POCUS) include its diagnostic accuracy in hemophilia, the dependence of operator training, agreement on scoring systems, and agreement on the value of POCUS in routine patient management. What are the published data to counter these potential barriers?

Magnetic resonance imaging (MRI) is currently the gold standard for detecting joint damage in PWH. Although MRI scans have been shown to have increased sensitivity in identifying hemophilic arthropathy compared with other types of radiography, the technique is very expensive and may require sedation in certain patient populations [Acharya et al. 2008]. However, US is a less expensive alternative to MRI scans, does not require sedation in pediatric patients, is a quick and reproducible study, and can obtain high-quality images dynamically to screen multiple joints at the same sitting [Acharya et al. 2008]. There is now general agreement that US performed by experienced operators correlates well with MRI in evaluating hemophilia joints, both with and without arthropathy [Acharya et al. 2008; Di Minno et al. 2013; Doria et al. 2015].

Ultrasound is highly operator-dependent and training is required to reduce inter-individual assessment variability, especially when not conducted by trained ultrasonographers [Doria et al. 2015]. Published papers comparing US with MRI [Acharya et al. 2008; Di Minno et al. 2013; Doria et al. 2015] report US conducted by trained radiologists. However, additional published studies in hemophilia in which US was performed by rheumatologists [Ceponis et al. 2013], other trained physicians [Aznar et al. 2011], and physiotherapists [Aznar et al. 2015] have also shown utility and accuracy when compared with trained personnel. It therefore appears that with sufficient training, POCUS can be accurately performed by nonphysicians, enhancing its usefulness in the clinical setting. The published uses of POCUS in hemophilia include evaluating a patient for a bleed versus nonbleed in adult patients presenting with a painful joint [Ceponis et al. 2013], and determining the duration of on-demand treatment for a bleed in adult patients [Aznar et al. 2015].

Despite the general agreement that prophylaxis is effective in severe hemophilia, it seems that adherence might benefit from a new approach. Could ultrasonic joint imaging, preferably at point-of-care with rapid feedback, be useful in promoting adherence to prophylaxis both in the case of a painful joint and joints judged ‘normal’ by the patient and caregiver? This commentary proposes a new use for US as an adjunct in supporting adherence to prescribed prophylaxis regimens. With respect to its use as an adjunct to managing PWH, POCUS should be defined as US conducted by a trained nonphysician operator with results interpreted rapidly and communicated to the patient by the physician at the same visit as part of the annual comprehensive visit treatment plan. The approach would be focused on answering specific clinical questions in a time-efficient, user-friendly manner. This type of US would therefore differ from a comprehensive US performed by imaging specialists [Martinoli et al. 2016]. The goal would be to devise a unique approach to comprehensive hemophilia care to promote patients’ compliance to prophylaxis or to modify the approach based on the US findings to preserve joint function.

For our stated proposal of using POCUS to support adherence, it is important to note two publications on the use of US in the management of hemophilia patients. In the first, a retrospective analysis in pediatric and adult patients, where the operator for the US was not specified, 304 joints judged normal by the Orthopedic Joint Score (Gilbert) revealed 38% of joints with US abnormalities [Muca-Perja et al. 2012]. In the second publication pertinent to the proposed use of POCUS to support adherence, Di Minno and colleagues studied PWH > 18 years of age and a comparator nonhemophilia group with US and MRI. The hemophilia group had clinically asymptomatic joints never involved with bleeding events (healthy joints) and an Orthopedic Joint Score of 0. US detected joint effusion in 55% of hemophilic arthropathic joints versus 5% of nonhemophilic joints (p < 0.001). The findings from US were confirmed via MRI scans. The findings of effusion, synovial hypertrophy, and cartilage erosions were higher in the PWH group with significant p values for trend. US and MRI data significantly correlated for effusion (r = 0.819;p = 0.002), synovial hypertrophy (r = 0.633;p = 0.036), and cartilage erosion (r = 0.734;p = 0.010) [Di Minno et al. 2013].

Scoring systems for US to guide the approach to the evaluation of joints in PWH have been proposed [Martinoli et al. 2016; Melchiorre et al. 2011]. In keeping with the suggestion that POCUS is different from a comprehensive US examination performed by trained radiologists and should deliver answers to specific clinical questions [Martinoli et al. 2016], is a scoring system feasible in this setting? A POCUS scoring system should be easy to learn and apply by nonphysicians and user-friendly. Melchiorre and colleagues have proposed a 9-point semiquantitative score that grades several findings that could be the target for a POCUS exam: joint effusion, synovial hypertrophy, with power Doppler to determine synovial vascularity, hemosiderin deposition, and structural bone and cartilage abnormalities [Melchiorre et al. 2011]. Groups studied were healthy individuals, PWH (pediatric patients and adults), and those with rheumatoid arthritis, and it appears (not specified) that the exams were performed by a nonradiologist physician. The time required was not mentioned. X-rays were performed and evaluated by the Pettersson score. Significant correlations were found for US versus the X-ray scores for several findings, including bone remodeling [Spearman’s rho correlation coefficient (SRCC), 0.429; p < 0.01] and osteophytes (SRCC, 0.308; p < 0.05).

The HEAD-US scoring system (additive score for synovial hypertrophy with emphasis on quantitative scoring of cartilage and bone changes) was developed with several goals important for a POCUS application: to be used by non-imaging specialists, fast to perform, and capable of screening six joints (elbows, knees and ankles) at a time [Martinoli et al. 2016]. The Hemophilia Joint Health Score (HJHS) was the comparator in a study of children with primarily severe disease. A strong correlation (r = 0.70, p < 0.01) was reported between HEAD-US and HJHS [Martinoli et al. 2016]. A short learning curve and the fact that HEAD-US examination needs <2 min per joint make it an excellent adjunct to physical examination for hemophilic arthropathy to detect early joint changes in which joint function is still preserved [Martinoli et al. 2016]. Despite these scoring systems and ability of POCUS to detect joint changes, a question that needs to be addressed includes ability of POCUS to detect changes attributed on MRI to subclinical joint bleeds reported in the absence of reported joint bleeding in the Joint Outcomes Study [Manco-Johnson et al. 2007].

In an effort to encourage prophylaxis-reluctant adults and teens to engage in a more routine regimen and adhere to that regimen, early detection of joint damage from recurrent bleeds by way of US can be used as a motivational tool to emphasize the importance of prophylaxis treatment and compliance by making use of the evidence of joint bleeds or lack thereof [Young, 2012].

Although there is no clinical trial evidence to support POCUS as a method to improve prophylaxis compliance, there is some published evidence that documents benefit to patients beyond seeing and discussing the findings on US. Ceponis and colleagues reviewed the usefulness of US examination of the hand in 51 adult patients with established rheumatoid arthritis [Ceponis et al. 2014]. Although termed point-of-care by the authors, the US examination was performed by experienced ultrasonographers who used a highly detailed approach that is different from the point-of-care concept described in this review. However, patient satisfaction documented in an exit questionnaire showed that 88.4% stated that the US examination increased their confidence in the clinical recommendations [Ceponis et al. 2014]. In a small exploratory study also in patients, age not specified, with rheumatoid arthritis [Thakkar et al. 2011], there was a greater perceived understanding with US (p < 0.007) and a positive trend toward increased compliance with their management plans (p < 0.066).

This commentary has documented the diagnostic accuracy of US as compared with MRI, the fact that nonphysicians can be trained to perform US accurately, and that US findings may contribute to the clinical care of PWH, often changing the approach to a given patient. Scoring systems have been developed and with further validation may be applicable to a POCUS setting with adequate training. Perhaps a next step might be to conduct a trial of POCUS in PWH in several centers using the HEAD-US system, preceded by training of nonphysician treatment team members in both US and the HEAD-US system. This trial should be conducted in patients from late teens to young adults, because the results in younger patients may differ.

Footnotes

Funding: Editorial assistance was provided by Complete Healthcare Communications, LLC (Chadds Ford, PA) and was fully funded by Bayer.

Conflict of interest statement: S. Acharya has received honoraria as a speaker in meetings organized by Novo Nordisk and Bayer and has served on advisory boards unrelated to this work. B. Rule and O. McMillan are full-time employees of Bayer. T. Humphries was a full-time employee of Bayer at the time the commentary was written.

Contributor Information

Suchitra S. Acharya, Hofstra Northwell School of Medicine, Cohen Children’s Medical Center of New York, 269-01 76th Avenue, Suite 255, New Hyde Park, NY 11040, USA.

Brittny Rule, Bayer, Whippany, NJ, USA.

Omar McMillan, Bayer, Whippany, NJ, USA.

Thomas J. Humphries, Bayer, Whippany, NJ, USA.

References

  1. Acharya S., Kaplan R., Macdonald D., Fabiyi O., Dimichele D., Lyden D. (2011) Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 117: 2484–2493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Acharya S., Schloss R., Dyke J., Mintz D., Christos P., Dimichele D., et al. (2008) Power Doppler sonography in the diagnosis of hemophilic synovitis - a promising tool. J Thromb Haemost 6: 2055–2061. [DOI] [PubMed] [Google Scholar]
  3. Armstrong E., Malone D., Krishnan S., Wessler M. (2015) Adherence to clotting factors among persons with hemophilia A or B. Hematology 20: 148–153. [DOI] [PubMed] [Google Scholar]
  4. Aznar J., Abad-Franch L., Perez-Alenda S., Haya S., Cid A., Querol F. (2011) Ultrasonography in the monitoring of management of haemarthrosis. Haemophilia 17: 826–828. [DOI] [PubMed] [Google Scholar]
  5. Aznar J., Perez-Alenda S., Jaca M., Garcia-Dasi M., Vila C., Moret A., et al. (2015) Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. Haemophilia 21: e147–e150. [DOI] [PubMed] [Google Scholar]
  6. Ceponis A., Onishi M., Bluestein H., Kalunian K., Townsend J., Kavanaugh A. (2014) Utility of the ultrasound examination of the hand and wrist joints in the management of established rheumatoid arthritis. Arthritis Care Res (Hoboken) 66: 236–244. [DOI] [PubMed] [Google Scholar]
  7. Ceponis A., Wong-Sefidan I., Glass C., Von Drygalski A. (2013) Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia 19: 790–798. [DOI] [PubMed] [Google Scholar]
  8. Di Minno M., Iervolino S., Soscia E., Tosetto A., Coppola A., Schiavulli M., et al. (2013) Magnetic resonance imaging and ultrasound evaluation of “healthy” joints in young subjects with severe haemophilia A. Haemophilia 19: e167–173. [DOI] [PubMed] [Google Scholar]
  9. Doria A., Keshava S., Mohanta A., Jarrin J., Blanchette V., Srivastava A., et al. (2015) Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. AJR Am J Roentgenol 204: W336–W347. [DOI] [PubMed] [Google Scholar]
  10. Manco-Johnson M., Abshire T., Shapiro A., Riske B., Hacker M., Kilcoyne R., et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544. [DOI] [PubMed] [Google Scholar]
  11. Martinoli C., Di Minno M., Pasta G., Tagliafico A. (2016) Point-of-care ultrasound in haemophilic arthropathy: will the HEAD-US system supplement or replace physical examination? Haemophilia 22: 20–21. [DOI] [PubMed] [Google Scholar]
  12. Melchiorre D., Linari S., Innocenti M., Biscoglio I., Toigo M., Cerinic M., et al. (2011) Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia 17: 112–117. [DOI] [PubMed] [Google Scholar]
  13. Muca-Perja M., Riva S., Grochowska B., Mangiafico L., Mago D., Gringeri A. (2012) Ultrasonography of haemophilic arthropathy. Haemophilia 18: 364–368. [DOI] [PubMed] [Google Scholar]
  14. Thakkar V., Joshua F., Bird P., Katrib A., Bertouch J. (2011) The role of ultrasound in patient understanding and compliance in early rheumatoid arthritis. Presented at: 51st Annual Scientific Meeting of the Australian Rheumatology Association (ARA), Melbourne, Australia. [Google Scholar]
  15. Young G. (2012) From boy to man: recommendations for the transition process in haemophilia. Haemophilia 18(Suppl. 5): 27–32. [DOI] [PubMed] [Google Scholar]

Articles from Therapeutic Advances in Hematology are provided here courtesy of SAGE Publications

RESOURCES